Leung W T, Shiu W C, Pang J C
Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong.
Med Oncol Tumor Pharmacother. 1990;7(1):31-4. doi: 10.1007/BF03000488.
Thirty-one patients with histologically proven small cell lung cancer were treated with cyclophosphamide 1 g m-2 and etoposide (VP16-213) 125 mg m-2 both intravenously on day 1 followed by etoposide 250 mg m-2 orally on days 2-3 for a maximum of six courses at 3 weekly intervals. Fourteen patients had limited and 17 patients had extensive disease. Twenty-five patients were evaluable for response. Objective response was observed in 18 patients (58%) with 6 (19%) complete and 12 (39%) partial responses. Median survival of the entire group of patients was 30 weeks. There was significant survival benefit among the responders (P less than 0.005) when compared with non-responders. One patient (3.3%) developed grade 4 while 60% of patients developed grade 1-2 haematological toxicity. Other side effects were relatively mild. We conclude that combination cyclophosphamide and etoposide was active in small cell lung cancer and relatively well tolerated.
31例经组织学证实的小细胞肺癌患者接受了如下治疗：环磷酰胺1 g/m²和依托泊苷（VP16 - 213）125 mg/m²均于第1天静脉注射，随后依托泊苷250 mg/m²于第2 - 3天口服，每3周为一个疗程，最多进行6个疗程。14例患者为局限性疾病，17例患者为广泛性疾病。25例患者可评估疗效。18例患者（58%）出现客观缓解，其中6例（19%）完全缓解，12例（39%）部分缓解。整个患者组的中位生存期为30周。与无反应者相比，有反应者的生存获益显著（P小于0.005）。1例患者（3.3%）出现4级毒性，而60%的患者出现1 - 2级血液学毒性。其他副作用相对较轻。我们得出结论，环磷酰胺与依托泊苷联合方案对小细胞肺癌有效且耐受性相对良好。
